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Compositionally and functionally distinct
sinus microbiota in chronic rhinosinusitis
patients have immunological and clinically
divergent consequences
Emily K. Cope1,3, Andrew N. Goldberg1, Steven D. Pletcher1 and Susan V. Lynch2*
Abstract
Background: Chronic rhinosinusitis (CRS) is a heterogeneous disease characterized by persistent sinonasal
inflammation and sinus microbiome dysbiosis. The basis of this heterogeneity is poorly understood. We sought to
address the hypothesis that a limited number of compositionally distinct pathogenic bacterial microbiota exist in
CRS patients and invoke discrete immune responses and clinical phenotypes in CRS patients.
Results: Sinus brushings from patients with CRS (n = 59) and healthy individuals (n = 10) collected during
endoscopic sinus surgery were analyzed using 16S rRNA gene sequencing, predicted metagenomics, and RNA
profiling of the mucosal immune response. We show that CRS patients cluster into distinct sub-groups (DSI-III), each
defined by specific pattern of bacterial co-colonization (permutational multivariate analysis of variance
(PERMANOVA); p = 0.001, r2 = 0.318). Each sub-group was typically dominated by a pathogenic family:
Streptococcaceae (DSI), Pseudomonadaceae (DSII), Corynebacteriaceae [DSIII(a)], or Staphylococcaceae [DSIII(b)]. Each
pathogenic microbiota was predicted to be functionally distinct (PERMANOVA; p = 0.005, r2 = 0.217) and encode
uniquely enriched gene pathways including ansamycin biosynthesis (DSI), tryptophan metabolism (DSII), two-
component response [DSIII(b)], and the PPAR-γ signaling pathway [DSIII(a)]. Each is also associated with significantly
distinct host immune responses; DSI, II, and III(b) invoked a variety of pro-inflammatory, TH1 responses, while DSIII(a),
which exhibited significantly increased incidence of nasal polyps (Fisher’s exact; p = 0.034, relative risk = 2.16),
primarily induced IL-5 expression (Kruskal Wallis; q = 0.045).
Conclusions: A large proportion of CRS patient heterogeneity may be explained by the composition of their sinus
bacterial microbiota and related host immune response—features which may inform strategies for tailored therapy
in this patient population.
Keywords: Microbiome, Sinus, Airway, Chronic rhinosinusitis, Cystic fibrosis, Colonization patterns, Predicted
metagenome, Dirichlet state, Microbiota state, Microbiota
Background
The field of human microbiome research has profoundly
altered our view of the diversity of human-associated
microbes and encoded functions, and demonstrated that
the microbiome co-varies with host health status [1–3].
In healthy subjects, a diverse bacterial microbiota
colonizes the upper respiratory mucosal surface [4, 5],
and the lower airways possess a low burden and diversity
of bacteria [6]. In contrast, patients with chronic inflam-
matory airway disease exhibit opposing trends in bacter-
ial diversity and burden and compositionally distinct
mucosal microbiota, enriched for known or suspected
pathogenic species, and related to features of pulmonary
disease [1, 5, 7, 8]. Chronic rhinosinusitis (CRS), charac-
terized by persistent inflammation of the sinonasal
mucosa lasting at least 12 weeks, is a common and
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refractory respiratory disease [9, 10], not least because of
the immunologic and clinical heterogeneity exhibited by
these patients. Until recently, little was known of the
microbiome of the sinus mucosa in either healthy subjects
or diseased patients. However, several recent culture-
independent studies have now demonstrated that loss of
sinus microbiota diversity is a common feature of patients
with CRS [5, 11, 12] and, independently, that greater pre-
operative sinus microbiota diversity is associated with
improved post operative outcomes [13]. Respiratory path-
ogens such as Pseudomonas aeruginosa or Staphylococcus
aureus are commonly isolated from CRS patients [14],
while pathobionts, such as Corynebacterium tuberculos-
tearicum, also found to be enriched in CRS patients, have
demonstrable capacity to induce sinus mucosal infection
in murine models [5]. However, these pathogens do not
exist in isolation, but in mixed-species mucosal microbiota,
the composition and activities of which, we hypothesize,
explain the substantial clinical and immunological hetero-
geneity observed in CRS patients.
Previous efforts to explain CRS patient heterogen-
eity have been based on clinical [15, 16], immunologic
[17–20], or pathologic [21] endotypes, though these
studies have been relatively small and focused on specific
immune cell populations or clinical features. More
recently airway studies have examined whether subject
stratification based on microbiota composition offers an
improved approach for understanding immunological or
clinical phenotypic variation across populations. A large
study (n = 234) of the infant nasopharyngeal microbiota
identified six compositionally distinct microbiota, each
dominated by a common respiratory bacterial genus and
associated with significantly different relative risk for acute
upper respiratory infection or development of asthma at
5 years [4]. Similarly, three compositionally and function-
ally distinct pathogenic lung microbiota have been de-
scribed in HIV-infected pneumonia patients (n = 182),
each co-associate with a specific host immune response
profile and differ in mortality risk [22]. Moreover,
predicted metabolic products characteristic of each of
these three distinct pathogenic lower airway communities
were found to be enriched in paired serum samples, indi-
cating that the microbiome of the overtly colonized airway
may actively contribute both to local and systemic
immune and metabolic dysfunction. The capacity for
meaningful stratification based on microbiota composition
is perhaps most compelling in a recent study of 1-
month-old infants (n = 130), who were divisible into
three distinct gut microbiota states, one of which con-
ferred a three-fold increased risk of atopy at the age of
2 years and asthma at the age of 4 years. The associated
products of the high-risk microbiota induced CD4 + IL4+
cell population expansion and CD4 +CD25 + FoxP3+ sup-
pression ex vivo [23]. Hence, several lines of investigation
suggest that patient immunological status and clinical out-
comes differ significantly based on the specific microbiota
structure present. Given these observations, we hypothe-
sized CRS patient heterogeneity may be explained by the
presence of distinct pathogenic sinus microbiota that in-
voke discrete host immune responses and relate to clinical
phenotypes. To address this hypothesis, we examined the
sinus mucosal microbiome and parallel host immune re-
sponses of a cohort of CRS and healthy subjects and re-
lated these findings to clinical outcomes of nasal
polyposis. We demonstrate the presence of distinct patho-
genic sinus microbiota in CRS patients each predicted to
encode unique functional attributes, which co-associate
with specific innate and adaptive immune responses, and
significantly different relative risk of nasal polyposis.
Methods
Study design
The UCSF Institutional Review Board (approval number
11-07750) approved this study. All participants were
informed of the objectives of this study and signed a
written consent form prior to their participation. Adult
patients (n = 76) undergoing endoscopic sinus surgery
(ESS) for CRS were enrolled at the University of California
San Francisco. Samples from two patients did not yield
PCR product, and five patients were removed from the
analysis due to low sequence depth. Therefore, 69 subjects
(10 healthy, 59 CRS patients) were included in down-
stream analysis (Table 1).
Patient enrollment and sample collection
Disease was clinically diagnosed according to the 2007
Rhinosinusitis Task Force guidelines [24], and severity
was radiographically quantified using the Lund-Mackay
Computed Tomography (CT) scoring system. All CRS
patients had symptoms for more than 12 consecutive
weeks and CT evidence of inflammation within a month
of sampling for this study. Patient demographics are
described in Table 1. Recent clinical history, sinonasal
outcomes test (SNOT-20), and CT sinus review were
collected and used to confirm CRS diagnosis. Recent
antibiotic use and intraoperative antibiotic administra-
tions were recorded at the time of sample collection.
Co-morbidities, including physician-diagnosed asthma
or cystic fibrosis (CF), were recorded. Sinus brushings were
obtained for 11 control patients undergoing surgery for
non-CRS etiologies including oral surgery, trans-sphenoidal
pituitary surgery, or endoscopic cerebral spinal fluid leak
repair. Endoscopically guided protected brushes (ConMed
#149, NY) were used to collect mucosal samples of the
diseased sinus by brushing each surface gently while rotat-
ing the brush five times. Each sample was immediately
placed in 1 ml of RNA later, transferred to 4 °C for 24–48 h
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Table 1 Demographics of CRS patients and healthy subjects included in this study
Sample ID Age Gender Disease Pre-operative antibiotics <3 months Lund-Mackay score Polyp Status
33 47 F CRS+CF Multiple (>3) 22 N Included
36 27 F CRS+CF Multiple (>3) 18 Y Included
39 28 M CRS+CF Multiple (>3) 13 N Included
61 20 M CRS+CF Azithromycin 15 Y Included
64 71 M CRS+CF Dicloxacillin 16 Y Included
83 24 M CRS+CF Multiple 19 Y Included
90 20 F CRS+CF Ceftrioxone 19 Y Included
91 47 M CRS+CF Zithromax/dapsone 17 Y Included
108 30 M CRS+CF Multiple (>3) 16 Y Included
1 41 M CRS Augmentin 5 N Included
7 39 F CRS Augmentin 12 N Included
8 55 F CRS+Asthma Augmentin 23 Y Included
15 55 M CRS+Asthma Clarithromycin 15 N Included
16 51 M CRS Augmentin 22 N Included
17 61 F CRS+Asthma Multiple (>3) 12 N Included
22 58 M CRS+Asthma Bactrim 12 Y Included
32 19 M CRS Augmentin 22 Y Included
34 51 M CRS+Asthma Levofloxacin 5 N Included
40 72 F CRS Tobramycin 9 N Included
43 46 M CRS Augmentin 12 N Included
44 62 M CRS Levofloxacin 20 Y Included
54 71 M CRS+Asthma dicloxacillin 13 Y <10,000 sequences/sample
55 68 F CRS+Asthma Clotrimazole 21 Y Included
56 67 F CRS Augmentin/Bactrim 14 Y Included
58 85 M CRS Ampicillin/sulbactam NDa ND No PCR product
59 42 F CRS+Asthma Clindamycin 4 Y Included
60 35 M CRS Multiple (>3) 16 N Included
63 77 F CRS Levofloxacin 6 N Included
80 58 M CRS Augmentin 8 N Included
81 65 F CRS+Asthma Augmentin 10 N Included
82 28 M CRS Augmentin 9 Y Included
85 24 F CRS+Asthma Augmentin 4 N Included
86 88 F CRS None 19 Y Included
88 73 M CRS None 21 Y Included
89 52 M CRS Clarithromycin ND ND No PCR product
92 59 M CRS Multiple (>3) 13 N Included
93 48 M CRS Azithromycin/augmentin 11 Y Included
94 72 F CRS+Asthma Augmentin 8 N Included
96 54 M CRS Cephalexin 11 Y Included
97 52 M CRS Cetirizine 22 Y Included
98 39 M CRS+Asthma Multiple (>3) 16 Y Included
99 57 M CRS Levofloxacin 16 Y Included
100 62 F CRS Bactrim 4 N Included
101 27 M CRS+Asthma Azithromycin ND Y Included
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to permit the nucleic acid preservative to permeate cells
prior to storage at −80 °C [25].
DNA extraction
Nucleic acids were extracted as previously described using
the AllPrep kit (Qiagen, CA), to purify DNA and RNA in
parallel [5, 25]. Briefly, brushes were placed in Lysis Matrix
B tubes in 600 μl Buffer RLT Plus with β-mercaptoethanol
and bead beaten for 30 s at 5.5 m sec−1 for nucleic acid ex-
traction per manufacturer’s protocol. DNA and RNA were
quantified using a NanoDrop 2000 (ThermoFisher, CA).
DNA concentrations were normalized to 50 ng μl−1 per
sample for 16S rRNA gene sequence library preparation,
described below.
16S rRNA gene library preparation
Barcoded primers 515 F/806R were used to amplify the
V4 region of the 16S rRNA gene as previously described
[26, 27]. Since double bands were present, one human
mitochondrial band and a microbial 16S band, ampli-
cons of the correct size (384 bp) were gel-extracted with
a Qiagen Gel Extraction kit per manufacturer protocol.
Purified PCR product was analyzed on Bioanalyzer (Aligent,
CA, USA), quantified using the Qubit HS dsDNA kit
(Invitrogen, CA, USA), and pooled at 25 ng per sample.
Table 1 Demographics of CRS patients and healthy subjects included in this study (Continued)
103 36 M CRS Augmentin 10 Y Included
104 23 M CRS None 12 N Included
105 18 M CRS None 21 N Included
107 37 F CRS Cephalexin 7 Y Included
109 71 M CRS+Asthma Augmentin 11 Y Included
110 18 F CRS Multiple (>3) 16 N Included
111 59 M CRS Augmentin 10 N Included
112 48 F CRS Augmentin 9 N Included
114 37 F CRS Clindamycin 1 N Included
115 26 F CRS Augmentin 3 N Included
117 33 M CRS Ciprofloxacin 19 N Included
120 50 F CRS+Asthma Multiple (>3) 15 Y Included
121 33 F CRS Augmentin 9 Y Included
122 45 F CRS+Asthma Augmentin 21 Y Included
123 74 M CRS+Asthma Augmentin 16 Y Included
124 30 M CRS+Asthma Augmentin 6 N <10,000 sequences/sample
126 43 F CRS+Asthma Augmentin 11 Y <10,000 sequences/sample
128 69 M CRS+Asthma Bactrim 21 Y Included
130 59 M CRS+Asthma Augmentin 17 Y Included
132 48 M CRS Rifampin 13 N <10,000 sequences/sample
143 61 M CRS Augmentin ND N Included
30 38 M Healthy Topical bacitracin ND N <10,000 sequences/sample
31 59 M Healthy Amoxicillin/azithromycin ND N Included
131 59 F Healthyb None 1 N Included
CRS14 41 M Healthyb None ND N Included
CRS15 39 M Healthy None ND N Included
CRS16 37 F Healthy None ND N Included
CRS17 46 F Healthy None ND N Included
CRS18 46 M Healthy None ND N Included
CRS19 31 F Healthy None ND N Included
CRS20 18 F Healthy None ND N Included
ctrl4 22 M Healthy None ND N Included
aND not determined
b Allergic rhinitis
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The pooled library was quantified using the KAPA
QPCR Illumina Library Quantification kit (KAPA
Biosystems, MA, USA), diluted to 2 nM, denatured,
and 5 pM was loaded onto the Illumina MiSeq
cartridge (V2) in combination with a 15% (v/v) of dena-
tured 12.5 pM PhiX spike-in. In addition to negative con-
trol extraction blanks, a mock community composed of
equal genomic concentration (2 ng each per reaction) of
Escherichia coli ATCC25922, P. aeruginosa ATCC27853,
C. tuberculostearicum ATCC35692, Lactobacillus sakei
ATCC15521, and L. rhamnosus ATCC53103 was also used
to monitor runs.
16S rRNA gene sequence processing
Sequence analysis of 16S rRNA data was performed
using Quantative Insights Into Microbial Ecology
(QIIME) version 1.8.0 [28] and in the R environment.
See Supplemental Methods for details.
Sequence and statistical analyses
Since our rarefaction curves approached an asymptote
(indicating adequate community coverage) at a se-
quence depth 10,055 sequences, and all but 5 samples
were sequenced at least to this depth, the operational
taxonomic unit (OTU) table was multiple rarefied to
10,055 high-quality, chimera-checked sequences per sam-
ple for subsequent analyses using a custom script (https://
github.com/alifar76/MicroNorm). All subsequent analyses
were performed on this rarefied table. UniFrac, Canberra,
and Bray-Curtis dissimilarity matrices were generated in
QIIME 1.8.0, and Principal Coordinates Analysis (PCoA)
plots were used to visualize ordinations using emperor
[29]. Permutational multivariate analysis of variance
(PERMANOVA) using the adonis function in the R
Vegan package was used to determine significance in
dissimilarity matrices across samples by metadata cat-
egories (e.g., disease, Dirichlet state, antibiotic use, age,
and disease severity [30, 31]). Faith’s phylogenetic diver-
sity, number of unique OTUs (richness), and Pielou’s
evenness were calculated and a permutational t test
(999 Monte Carlo permutations) was used to determine
changes in alpha diversity. When multiple comparisons
were performed, we corrected for false discovery using
the Benjamini-Hochberg method and reported the
corrected p values as q values, a q < 0.05 was considered
significant [32]. Changes in taxon relative abundance were
determined per OTU using a zero-inflated negative
binomial (https://github.com/alifar76/NegBinSig-Test) dis-
tribution on a regression model. Kruskal-Wallis was used
to determine if statistically significant differences in OTU
or Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway abundances existed between more than two
groups, such as healthy patients, CRS, and CRS+CF pa-
tients. To identify clusters, the Dirichlet-multinomial
mixtures probabilistic community modeling was per-
formed using the DirichletMultinomial package [33] in
R with family-level taxonomy using absolute abun-
dances of each family. The Laplace approximation was
used to calculate model fit and to determine the num-
ber of components (clusters). Distinct sample clusters
that represented the best model fit were termed Dirichlet
states (DS). To determine whether DSIII could be
separated into two phylogenetically distinct groups,
hierarchical cluster analysis was performed on a
weighted UniFrac distance matrix using an edited version
of pvclust in R (code attached in Additional file 1,
Additional file 2, Additional file 3, Additional file 4,
Additional file 5). Kruskal-Wallis was used to determine
whether host genes were significantly up- or down-
regulated in disease. Statistical analysis was performed
using R.
Predicted metagenomics
Metagenome prediction from the closed-reference
OTUs (greengenes 13_5) of the multiple rarefied OTU
table was performed using the Phylogenetic Investigation
of Communities by Reconstruction of Unobserved States
(PICRUSt v. 1.0.0 [34]). QIIME 1.8.0 was used to analyze
the predicted metagenomes. Differential abundances of
pathways were tested using a Kruskal-Wallis test when
comparing more than two groups or a three-model
approach (negative binomial, zero-inflated negative bino-
mial, or poisson distributions) applied on a regression to
test pairwise comparisons. Model fit was determined
using Akaike information criterion (AIC) values, and the
associated statistic was reported (https://github.com/ali
far76/NegBinSig-Test). Nearest Sequenced Taxon Index
(NTSI) scores were calculated using the –a flag in
metagenome_predictions.py. These represent the average
branch length separating OTUs in a sample from a ref-
erence bacterial genome. A heatmap was constructed for
KEGG categories that were enriched or depleted in each
disease state using heatmap.3 in R. For visualization,
read counts were normalized [log2(x + 1)] and scaled by
row. See Additional file 6: Supplemental Methods for
more detail.
Quantitative PCR for bacterial burden and human gene
expression
Quantitative PCR (qPCR) was used to quantify bacterial
burden as a ratio to human beta-actin. See Supplemental
Methods for primers and PCR conditions. A custom
qPCR array was developed (SA Biosciences, Hilden,
Germany) and used to quantify host gene expression
using RNA extracted in parallel from patient sinus
brushes. See Additional file 6: Supplemental Methods
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for gene targets and reverse transcriptase (RT) PCR
conditions.
Results
Sinus mucosal microbiome perturbations characterize
CRS and are related to disease status
Our cohort consisted of 76 subjects. Sixty-five were CRS
patients and 11 were healthy subjects. CRS patients
included those with concomitant lower airway disease
i.e. cystic fibrosis (CRS+CF) or asthma (CRS+A; Table
1). Sinus brushing samples from 2 subjects yielded no
16S rRNA amplicons (both from CRS patients), and a
further 5 samples were removed due to low sequence
depth (<10,000 sequences/sample; n = 4 CRS and n = 1
healthy). Thus, 10 healthy individuals and 59 CRS patients
were included in the analyses presented.
CRS patients exhibited signifcantly higher Lund
McKay scores compared to healthy subjects (p<0.05),
however amongst CRS patients, disease severity did not
differ based on the presence or absence of concomitant
lower airway disease (Tukey’s post hoc comparison; p >
0.05, Additional file 6: Figure S1A). Mucosal bacterial
burden (based on total 16S rRNA copy number) was not
significantly different across healthy and CRS patients
(ANOVA; p = 0.781; Fig. 1a), consistent with previous re-
ports [5, 12]. Also consistent with previous findings [5,
12] was the observation that compared with healthy
subjects, CRS patients exhibited significantly lower
microbiota richness, evenness, and diversity. Of note, di-
minished alpha diversity in CRS patients was more pro-
nounced in those with concomitant lower airway disease
(permutational t test; all p < 0.01; Fig. 1b–d). Multivari-
ate analysis (PERMANOVA) of sinus bacterial beta di-
versity on a weighted UniFrac distance matrix was used
to determine whether factors such as age, antimicrobial
administration, polyposis, revision surgery (a complete
list is provided in Table 2) explained the observed vari-
ation in community composition across all subjects
(CRS and healthy), or exclusively within the CRS pa-
tients. Of these, only disease status (healthy, CRS, CRS
+CF, CRS+A) was significantly related to beta diversity,
but only explained a small portion of microbiota com-
positional variance and the effect size was small (PER-
MANOVA; p = 0.001, 8.9% of variation explained,
Fig. 1e; Table 2).
Discrete pathogenic sinus microbiota exists in CRS patients
We postulated that the microbiota dysbiosis exhibited by
CRS patients does not represent a single state, but rather
a gradient of dysbioses punctuated by a limited number of
distinct pathogenic microbiota compositional states. We
addressed this hypothesis through the application of an
unbiased probabilistic model, Dirichlet-multinomial mix-
tures (DMM) [33] which identifies clusters of samples
a
c
b
d
e
Fig. 1 CRS patients (irrespective of lower airway disease status) exhibit similar total bacterial burden compared with healthy subjects; however, their
microbiota exhibit significantly reduced richness, evenness and diversity. Comparative analyses of sinus microbiota a bacterial burden; b richness (permutation
t test; CRS vs healthy q= 0.006; CRS+A vs healthy, q= 0.0015 CRS+CF vs healthy, q= 0.0015); c Pielou’s evenness (permutation t test; CRS vs healthy q= 0.132,
CRS+A vs healthy, q= 0.015 and CRS+CF vs healthy, q= 0.003]), and d Faith’s phylogenetic diversity (permutation t test; CRS vs healthy, q= 0.007, CRS+A vs
healthy, q= 0.003 and CRS+CF vs healthy, q= 0.003) indices using V4 16S rRNA amplicon sequencing of healthy, CRS, CRS+A and CRS+CF subjects. Values
represent the median +/− 1.5 IQR. e Multivariate permutation testing of principal coordinate analysis using PERMANOVA based on a weighted UniFrac
distance matrix of all samples indicates that disease status explains 8.9% of community composition variation (p= 0.001)
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based on bacterial community composition. Based on a
Laplace approximation, three distinct sample clusters,
termed Dirichlet states (DSI-III) represented the best
model fit (Additional file 6: Figure S3A); DSI comprised
26 subjects (n = 9/10 healthy, n = 17 CRS), DSII comprised
14 CRS patients, and DSIII comprised 28 CRS patients
and one healthy subject. Upon chart review, it was noted
that this particular healthy subject had allergic rhinitis. DS
clusters were confirmed as compositionally distinct by
PERMANOVA (weighted UniFrac PERMANOVA; p =
0.001, 31.8% variation; Fig. 2a), a finding that was robust
irrespective of the distance matrix used to analyze the 16S
rRNA data (Table 3, Additional file 6: Figure S2A).
Both weighted and unweighted UniFrac distance matrices
significantly explained DS-defined sample clustering, indi-
cating that both bacterial phylogeny and rarer taxa in
these communities discriminated DS groups. To further
confirm this, sequence reads associated with the dominant
family in each sample were removed and the data reana-
lyzed. DS classification remained significantly related to
community composition (weighted UniFrac PERMA-
NOVA; p = 0.001, 18.2% variation; Additional file 6: figure
S2B) indicating that patterns of co-associated lower abun-
dance taxa are discrete and relatively conserved within
each of the three DS microbiota.
The proportion of healthy subjects and CRS patients
with or without pulmonary co-morbidities varied signifi-
cantly across DSI-III (Chi-squared; p = 0.0007; Fig. 2b),
with DSI possessing the least and DSII the greatest pro-
portion of CRS patients with concomitant lower airway
disease (CRS+CF and CRS+A). This implicates a co-
association between specific pathogenic sinus commu-
nity states and lower airway disease and also provides
the first evidence that specific pathogenic sinus micro-
biota are common to both CF and asthmatic patients.
While recent antibiotic use trended towards significance,
it only explained a very minor portion of community
compositional variance (PERMANOVA; p = 0.052, r2 =
0.036; Table 2) and did not differ across DSI-III (Chi-
squared; p = 0.149). This is likely because these micro-
biota exist in antimicrobial resistant biofilms on the
sinus mucosal surface [35]. Disease severity, as measured
by Lund-Mackay radiographic scores also did not differ
across DSI-III (ANOVA p = 0.825), suggesting that distinct
pathogenic microbiota may drive equally severe disease
symptoms, albeit via distinct mechanisms (it should be
noted that these patients were undergoing functional
endoscopic sinus surgery at the time of sample collection).
DSIII was the largest group and was comprised of
patients whose sinus mucosal microbiota represented
a compositional continuum dominated by either
Staphylococcaceae (Firmicutes) or Corynebacteriaceae
(Actinobacteria). Since these taxa are phylogenetically
distinct, are known competitors in the upper airways
[36, 37], and elicit unique immune responses [38], we
identified Corynebacteriaceae- or Staphylococcaceae-
dominated patients within this group as distinct DSIII
sub-groups, identified as DSIII(a) (n = 9) or III(b) (n = 19;
Fig. 2b), respectively. This sub-grouping strategy was
statistically supported by hierarchical clustering analysis
on a weighted UniFrac distance matrix (au, p < 0.05;
Additional file 6: Figure S3B), and we confirmed the
existence of a reciprocal relationship between Corynebac-
teriaceae [DSIII(a)] and Staphylococcaceae [DSIII(b)]
relative abundance across DSIII samples (Additional
file 6: Figure S3C).
Each pathogenic microbiota state (DSI-III) was charac-
teristically dominated by a distinct bacterial family that
co-associated with a relatively unique suite of lower
abundance taxa (Fig. 2c). To identify taxonomic differen-
tials characteristic of each CRS microbiota state, each
was compared to healthy subjects using zero-inflated
negative binomial (ZINB) regression (Fig. 2d–g,
Additional file 3). The identity and magnitude of de-
pleted taxa was relatively consistent irrespective of the
CRS microbiota state examined and included Streptococ-
cus, Rothia, Haemophilus, and Lactobacillales members
(ZINB; p < 0.05, q < 0.10; Fig. 2d–g). The magnitude and
types of taxa enriched in CRS patients differed by
Table 2 Multivariate analysis (PERMANOVA) of sinus bacterial
beta diversity on a weighted UniFrac distance matrix
PERMANOVA (patient cohort) r2 p value
Dirichlet state (diseasea) 0.326 0.001
Dirichlet state (allb) 0.318 0.001
Disease (all) 0.088 0.014
Antibiotic use <3 months (disease) 0.036 0.052
Polyp presence/absence (disease) 0.025 0.152
Anatomic location (all) 0.039 0.185
Age bin 10 year (all) 0.118 0.196
Antibiotic class <3 months (all) 0.260 0.24
Age bin 5 year (all) 0.153 0.367
Antibiotic class <3 months (disease) 0.286 0.399
Anatomic location (disease) 0.0348 0.403
Age bin 10 year (disease) 0.119 0.473
Age bin 5 year (disease) 0.168 0.521
LMS Bin (low/medium/high) (disease) 0.046 0.554
Revision surgery (Y/N) (disease) 0.042 0.668
Age (disease) 0.674 0.799
Lund-Mackay score (LMS) (disease) 0.327 0.906
Age (all) 0.561 0.944
aCRS, CRS+CF, CRS+A
bHealthy, CRS, CRS+A, CRS+CF
Those in boldface are significant (the r2 value indicates the degree of
community variance explained by the specific factor)
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community state (Fig 2c) and were most pronounced in
DSIII(a) and III(b), which exhibited relatively large
Corynebacterium or Staphylococcus enrichments, respect-
ively. DSI, though most compositionally similar to healthy
controls, exhibited relative enrichment of Streptococcus as
well as Porphyromonas, Tannerella, Treponema, Bacter-
oides, Dialister, and Akkermansia (ZINB; p < 0.05, q <
0.05). DSII, dominated by Pseudomonadaceae, was also
relatively enriched for Fusobacterium, Aggregatibacter,
Achromobacter, and Prevotella (ZINB; p < 0.05, q < 0.05),
known airway pathobionts characteristically enriched in
CF and asthmatic lungs [1, 7, 39, 40]. Presumably, this
reflects the increased number of such patients in this sub-
group and indicates that archetypal lower airway micro-
biome dysbioses in CF and asthmatic patients may also be
reflected in the upper airway bacterial community
composition of these patients. While DSIII(a) and III(b)
shared substantial taxonomic overlap, explaining their stat-
istical grouping into a single DMM cluster, DSIII(a) was
uniquely enriched for Sphingomonas (ZINB; p < 0.0001, q
< 0.0001; Fig. 2f) and DSIII(b) uniquely co-enriched for
eight taxa absent in III(a) [Actinobacteria, Bifidobacterium,
Haemophilus, Enterobacteriaceae, Pseudomonadaceae,
Sphingomonadaceae (unclassified genus), Selenomonas,
and Streptophyta (ZINB; p < 0.05, q < 0.05; Fig. 2g)].
Because the majority of healthy individuals were classi-
fied into DSI, we also compared DSII, III(a) and III(b)
individually to DSI. General concordance was observed
between taxa enriched in DSII or III when compared to
either DSI or healthy subjects (ZINB; p < 0.05, q < 0.05;
Additional file 6: Tables S1-S3). The primary discrimin-
ating genera for each DS remained consistent; differ-
ences were only observed in a select few low abundance
taxa, validating the observation that the DSI microbiota
was compositionally similar to that of healthy subjects.
When compared to DSI, DSII remained enriched for
Aggregatibacter, Achromobacter, Fusobacterium, and Pre-
votella but was also relatively enriched for Pseudomonas
(ZINB; p = 0.004, q = 0.026). DSIII(a) and III(b) remained
highly enriched for Corynebacterium or Staphylococcus
although Cloacibacterium were uniquely co-enriched
with Corynebacterium and Serratia were uniquely co-
enriched with Staphylococcus when these groups were
compared with DSI.
Predicted functional capacity discriminates sinus bacterial
Dirichlet states
Bacterial metagenomes were predicted in silico for each pa-
tient using PICRUSt, an algorithm which uses biomarker
gene sequence data i.e., 16S rRNA to infer evolutionarily
conserved functional gene capacity using representative se-
quenced and predicted ancestral genomes. Associated
Nearest Sequenced Taxon Index (NTSI) scores which indi-
cate the degree of relatedness between OTUs and se-
quenced genomes used for PICRUSt predictions are
detailed in Additional file 7. Each microbiota state was
predicted to encode a distinct metagenome (Bray-Curtis
PERMANOVA; p = 0.001, 23.2% variation explained;
Additional file 6: Figure S4) and a total of 196 KEGG
pathways differentiated pathogenic microbiota states
compared control patients (three-model test; p < 0.05,
q < 0.10; Fig. 3a). Only 21 KEGG pathways discrimi-
nated patients with distinct lower airway co-
morbidities (asthma+/−, CF; Kruskal-Wallis; p < 0.05,
q < 0.10; Additional file 6: Table S4), indicating sub-
stantial overlap in sinus microbiota function in the
upper airways of CRS patients with distinct lower air-
way diseases. Compared to healthy microbiota, the
DSII group was the least functionally diverse (permu-
tational t test; q < 0.05; Fig. 3b) and depleted of 67
KEGG pathways for lipid, carbohydrate, terpenoid, and
xenobiotic metabolism. DSII and III(b) were both sig-
nificantly enriched in bacterial virulence pathways, includ-
ing two-component response systems, and for fatty acid
and tryptophan metabolism pathways associated with in-
flammation (negative binomial; p < 0.05, q < 0.05;
Fig. 3c–d, Additional file 6: Table S5), when com-
pared to healthy controls. DSI patients were depleted
of polyketide and folate biosynthesis and enriched for
a pathway responsible for ansamycin biosynthesis, a
(See figure on previous page.)
Fig. 2 Dirichlet-multinomial mixtures modeling identifies microbial states that explain a large portion of variation in microbiota composition. a
Multivariate permutation (PERMANOVA) testing of DS designation (I-III(b)) explains 31.8% of variation in sinus mucosal microbiota composition
(p = 0.001). The most abundant family-level taxa are indicated. Size of sphere is proportional to the average relative abundance of each dominant
taxon. b Distribution of co-morbidities (CF or physician-diagnosed asthma) signifcantly differ across microbiota states. DSI was represented by CRS
patients and 9/10 of the healthy controls. DSII was enriched for CRS+CF and CRS+A patients, whereas DSIII was comprosed primarily of CRS pa-
tients without concomitant lower airway disease, and one healthy control subject (Chi-squared; p = 0.0007). c Stacked bar chart indicating the dis-
tribution of taxa in the sinuses grouped by DS. d–g Three-model testing of differential taxon abundance indicates that each DS is associated with
enrichment for specific taxa and co-colonizers and depletion of microbiota associated with healthy individuals (ZINB; p < 0.05, q < 0.10)
Table 3 Weighted and unweighted UniFrac distance matrix
PERMANOVA (Dirichlet states) r2 p value
Weighted UniFrac 0.326 0.001
Unweighted UniFrac 0.182 0.001
Bray-Curtis 0.195 0.001
Canberra 0.099 0.001
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microbial secondary metabolite with a broad range anti-
microbial activity (poison; p < 0.0001, q < 0.0001; Additional
file 6: Table S5A) [41]. Corynebacterium-dominated
DSIII(a) was characterized by both peroxisome proliferator-
activated receptor-γ [(PPAR-γ) negative binomial; p = 0.003,
q = 0.018; Fig. 3e, Additional file 6: Table S5C] and the
retinoic acid-inducible gene-1 (RIG-I) signaling pathways
(negative binomial; p = 0.015, q = 0.062; Additional file 6:
Table S5C), both of which have been shown to be increased
in eosinophilic polyp tissue in CRS patients [42, 43].
Sinus microbial communities correlate with clinical
outcomes
Bacterial community composition within the cohort did
not correlate with polyposis (weighted UniFrac; PERMA-
NOVA; p = 0.152, 2.5% variation; Fig 4a). However, based
on the microbiota and predicted metagenome data, specif-
ically, the enrichment of RIG-I and PPAR-γ signaling
pathways (previously associated with polyposis) in the
Corynebacterium-dominated DSIII(a) patients, we pre-
dicted that these patients would exhibit significantly in-
creased incidence of polyposis. We therefore performed
an assessment of polyp relative risk across microbiologic-
ally discrete CRS patient sub-groups compared to DSII
patients, who possessed compositionally similar micro-
biota to those of healthy subjects and the lowest incidence
of polyposis (41%; 7 of 17 patients). As expected, the
DSIII(a) sub-group exhibited a significantly higher rela-
tive risk of polyposis compared to all of the other
microbiologically defined patient sub-groups, with 89%
(8 of 9 patients) of patients in this group exhibiting
polyposis (Fisher’s exact; relative risk = 2.159, p = 0.039;
Fig 4b).
Bacterial co-colonization patterns correlate with patterns
of host gene expression
To determine, as we hypothesized, whether distinct DS-
induced discrete host immune responses, we used qPCR
to measure expression of innate and adaptive genes pre-
viously associated with CRS (Th1, Th2, Th17 and Treg
cytokines, mucin, and epithelial barrier genes) using
RNA extracted in parallel with DNA used to profile mi-
crobial communities from sinus brushings of all subjects.
Fold change in gene expression (compared to healthy
a b
c d e
Fig. 3 Variation in predicted metagenomes associated with each Dirichlet state. a Heatmap of significantly enriched (red) or depleted (blue) KEGG
pathways collapsed at level 3 compared to healthy subjects (negative binomial; p< 0.05, q< 0.10, DS vs. nonCRS). For visualization, read counts were
normalized [log2(x+ 1)] and scaled by row. b DSII is significantly functionally depleted, measured by total unique KEGG pathways compared to healthy
individuals (permutational t test; q= 0.0025). c Tryptophan metabolism is enriched in DSII [Pseudomonadaceae-defined, (negative binomial; p= 0.021,
q= 0.059)] and DSIII(b) [Staphylococcaceae-defined (negative binomial; p= 0.005, q= 0.012)]. d The two-component response system virulence pathway
is enriched in DSII [Pseudomonadaceae-defined, (negative binomial; p= 0.0002, q= 0.002)] and DSIII(b) [Staphylococcaceae-defined (negative binomial;
p= 0.0002, q= 0.002)]. e PPAR-γ signaling pathway is enriched in DSIII(a) [Corynebacteriaceae-defined (negative binomial; p= 0.003, q= 0.0175)]
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subjects) was used to generate a multivariate immune
response profile for each subject.
Each CRS DS group exhibited a significantly distinct
host immune response, the specifics of which varied
across CRS patient sub-groups (Fig. 4c; full array in
Additional file 6: Figure S5). DSI, II, and III(b) patients
exhibited significantly increased IL-1β, implicating
macrophage and inflammasome involvement in these
patients. In addition to IL-1β, patients in DSII also
exhibited increased IL-6, TNF-α, IL-8, and IL-10
expression (Kruskal-Wallis; p < 0.05, q < 0.05), suggestive
of an epithelial/endothelial and/or macrophage-driven
mucosal inflammatory response. DSI patients, whose
microbiota composition differed subtly in taxonomic
content from healthy individuals, were immunologically
distinct and exhibited significantly increased IL-1β, IL-6,
and IL-10 compared to healthy individuals (Kruskal-
Wallis; p < 0.05, q < 0.05). Thus, subtle taxonomic differ-
ences may influence the activity of this microbiota, or,
alternatively, non-bacterial microbiota members
may contribute to immune-stimulation in this subset of
patients. DSIII(a) patients who are at higher relative risk
for polyposis and whose sinus mucosal microbiome
was enriched for Corynebacterium and predicted to
encode PPAR-γ and RIG-I signaling pathways were
the only group to exhibit a significant increase in IL-
5 expression (Kruskal-Wallis; p < 0.05, q < 0.05;
Fig 4d). IL-5 is a potent activator of eosinophils, the
dominant immune cell type in polyp tissue in West-
ern populations of CRS patients [44]. Furthermore,
these patients also had increased levels of IFN-γ
(Kruskal-Wallis; p = 0.017, q = 0.107), which has been
associated with non-eosinophilic polyposis [45].
Collectively, these findings indicate that distinct dys-
biotic pathogenic bacterial microbiota states exist in
CRS patient sub-groups that differ in relative risk for
polyposis and induce discrete immune responses re-
lated to their clinical phenotypes.
Discussion
Clinical diagnosis of CRS is somewhat subjective and often
does not correlate well with patient outcomes [19]. Im-
proved stratification of patients offers the opportunity to
better tailor therapeutic regimens and advance towards the
ultimate goal of personalized therapy. A previous study of
the CRS-associated microbiota demonstrated evidence for
mucosal microbiota collapse in patients with severe disease
and enrichment of C. tuberculostearicum [5]. That study
also noted that though the number of CRS patients was
very small, they parsed into two distinct groups based on
sinus microbiota composition. In the current study, we val-
idate previous findings and extend them, demonstrating
that the CRS bacterial microbiota can exist in at least four
distinct taxonomic states (one of which is dominated by
Corynebacteriaceae). We suspect that these represent a
gradient of pathogenic microbial co-colonizations that are
related to patient treatment history and/or disease progres-
sion. Previous CRS microbiota studies have described high
inter-patient taxonomic variability and dominance of com-
mon respiratory pathogens Corynebacterium, Staphylococ-
cus, Pseudomonas, and anaerobes such as Fusobacterium
and members of Prevotellaceae [11–13, 46, 47]. These gen-
era also feature prominently in our study, but we expand
upon these findings to demonstrate that these respiratory
pathogens co-associate with distinct and reproducible
microbial partners and explain a large proportion of the
a b c
Fig. 4 Microbial states confer a differential risk for polyposis and are significantly associated with distinct profiles of host immune
response. a Multivariate permutation (PERMANOVA) testing of presence or absence of polyps at time of surgery does not indicate a
significant relationship at the whole-community level (p = 0.152, 2.5% variation explained). b Patients with DSIII(a) have a significantly
increased risk for polyposis (88.9% of patients have polyps; Fisher’s exact; p = 0.032, relative risk = 2.159 compared to DSI). c Heatmap
of Z score-normalized mean fold change (2−ΔΔCt) for each gene examined indicates that immune responses distinct from that of healthy
subjects are evident in CRS patients; samples are grouped by DS and healthy individuals (*indicates Kruskal-Wallis; p < 0.05, q < 0.15;
**indicates Kruskal-Wallis; p < 0.05, q < 0.05; DS vs. nonCRS)
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observed inter-personal microbiota variation in CRS
patients. These microbiologically distinct states are pre-
dicted to encode different metagenomes, are associated
with a characteristic innate and adaptive host immune
response, and differ significantly in the incidence of nasal
polyposis, an important clinical phenotype of CRS.
Approximately one fifth of CRS patients had a mucosal
microbiota characteristically enriched for Corynebacteria-
ceae and depleted of Streptococcus. Lemon and colleagues
recently demonstrated that Corynebacterium accolens, a
common skin commensal, metabolizes triacylglycerols in
nasal secretions to oleic and linoleic acid, which inhibits
Streptococcus pneumoniae growth [48]. Metagenome
predictions indicated that the Corynebacteriaceae OTUs
in dysbiotic CRS patient microbiota also encode the cap-
acity for linoleic acid biosynthesis, suggesting that this
mechanism of Streptococcus inhibition may play a role in
deterministically shaping the pattern of co-colonizing
species around this dominant respiratory pathogen in the
chronically inflamed sinus microbiota. However, further in
vitro and in vivo studies are required to determine
whether this mechanism plays a role in defining CRS
microbiota composition. Independent of this pathway, a
recently described phylogenetic-related species, Cor-
ynbecterium pyruviciproducens, has been shown to
stimulate dendritic cell maturation and proliferation
and up-regulate Th2 responses in mice [49]. Additionally,
the lipoarabinomannan-based lipoglycans of Corynbecter-
ium glutamicum induce Th17 responses via TLR2 recog-
nition on dendritic cells [50], indicating several discrete
pathogenic pathways exist in this genus. In our study,
Corynebacteriaceae-defined microbial communities were
enriched in PPAR-γ and RIG-I pathways. PPAR-γ, a lipid-
sensing receptor, controls gene expression and metabol-
ism and has recently been shown to regulate eosinophil
activation in polyp tissue of CRS patients [42]. It has also
been associated with asthma [51] and airway remodeling
following allergic inflammation in mice [52]. RIG-I, an
intracellular sensor of viral DNA, is elevated in nasal
polyp tissue [43] and is induced by IFN-γ [53]. Consistent
with these observations, patients possessing a Corynebac-
teriaceae-dominated community state were uniquely asso-
ciated with increased IL-5 and IFN-γ gene expression and
were at a higher risk for developing polyposis. Mounting
evidence suggests that members of this family, particularly
in the context of a taxonomically and functionally de-
pleted sinus microbiota, represent a group of underappre-
ciated pathobionts, whose activities induce TH2-skewed
immune responses.
Of the remaining DMM-identified microbial states,
patients classified into DSII (Pseudomonadaceae-domi-
nated) were the least functionally diverse, the most im-
munologically active, and housed the greatest proportion
of CF and asthma patients, who also commonly exhibit
lower airway microbiota dominated by this family.
Predicted functional enrichments in DSII included path-
ways involved in tryptophan metabolism and lipopoly-
saccharide biosynthesis, both of which induce host
inflammatory responses [54]. For example, recent studies
have demonstrated that HIV-infected patients with the
greatest degree of peripheral immune activation are
enriched for Pseudomonas species in their gastrointes-
tinal microbiota and that isolates of Pseudomonas from
these patients exhibit the capacity to catabolize trypto-
phan to pro-inflammatory kynurenine in vitro [55, 56].
Interestingly, other co-colonizing members of the DSII
community are known producers of tryptophan e.g.,
Achromobacter [57], implicating metabolic cross-feeding
between the dominant respiratory pathogen and it's co-
colonizers as a deterministic mechanism that plaus-
ibly underlies their frequent co-association in Pseudo-
monas-dominated sinus microbiota. Additionally,
tryptophan metabolites increase biofilm formation [58,
59] and virulence gene expression [60, 61], indicating
that enhanced capacity for the production and metabol-
ism of this crucial amino acid by co-associated members
of this community state may be critical to enhanced
antimicrobial resistance and pathogenicity. Immuno-
logically, patients in DSII, which had the highest preva-
lence of CRS+CF patients, exhibited increases in genes
associated with neutrophil and macrophage activation,
including TNF-α and IL-8, which is consistent with CF
airway immune responses associated with strains of P.
aeruginosa specifically adapted to the lung environment
[62, 63]. IL-1β gene expression was increased in DSI, II,
and III(b), which may indicate a role for inflammasome
activation in CRS patients with TH1-skewed disease.
Inflammasomes are multi-meric protein complexes that
assemble in cells to control the production of IL-1β and
IL-18 following activation by pathogen-associated mo-
lecular patterns (PAMPs), such as peptidoglycan [64].
The goal of this study was to better understand CRS
patient heterogeneity by leveraging high-resolution
microbiota profiles to stratify patients into discrete sub-
groups and to determine whether such a stratification
strategy explained immunological and clinical outcomes
in these patients as has been demonstrated in other
chronic diseases [4, 22, 23, 65]. We demonstrate the
existence of distinct microbiota states and show that
they are robust and encode unique functional attributes
that correlate with mucosal immune responses and clin-
ical outcomes. We recognize that this cross-sectional
study cannot address whether these microbiota states
are stable or transient; however, it is plausible that they
represent a gradient of pathogenic bacterial community
successional states associated with disease progression.
It will be interesting to determine whether medical
management of CRS, such as antimicrobial treatment or
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surgery, alters a patient’s microbiota state and associated
inflammatory response towards that of a different con-
formation and whether the states we have identified are
in fact related to disease progression or duration. Antibi-
otics can rapidly and pervasively shift the composition
of the microbiota in the human gut [66, 67] and can in-
fluence sinus microbial composition, at least in the short
term [68]. Future studies will examine the effects of
medical and surgical management of CRS on the stabil-
ity of the disease microbiota. Although concomitant
lower airway co-morbidities (asthma or CF) explained a
small portion of beta diversity variation, we demonstrate
that some asthmatics and cytsic fibrosis patients share
the same sinus microbiot a state. This observation sug-
gests that subsets of patients with clinically distinct re-
spiratory diseases share the same pathogenic microbiota
and host immune response. The concept that discrete
respiratory diseases have overlapping pathophysiology
has been recently explored in asthma and chronic ob-
structive pulmonary disease (COPD) [69, 70]. Our data
suggests this phenomenon may extend to CF and be ex-
plained, at least in part, by overlapping microbiota
colonization states. Furthermore, enrichment of Proteo-
bacteria in the lower airways patients with established
asthma or CF is well documented [7, 71, 72]; our find-
ings demonstrate that lower airway bacterial biomarkers
of these respiratory diseases exist in the upper respiratory
tract, which may represent a source of pathogenic mi-
crobes for lower airway colonization. Future studies will
incorporate more thoroughly characterized asthmatics,
since asthma immune subtypes are well described and
may plausibly be explained by the microbiota states ob-
served in our study [73].
In this initial study, we did not profile viral or fungal
components of these microbiota states, which also likely
play a role in driving the observed bacterial heterogeneity
or host immune response. We also recognize the limita-
tions of using a predictive algorithm to infer metagenome
content, particularly since PICRUSt has been most
thoroughly studied in the GI tract, (though PICRUSt pre-
dictions on nasal samples from the Human microbime
Project have been shown to be robust when compared to
shotgun metagenome sequencing [33]). Future studies will
use shotgun metagenomics and transcriptomics ap-
proaches to confirm PICRUSt-predicted metagenomes as
well as to identify viral and fungal taxa in these patients.
We anticipate that metagenomics, in parallel with meta-
bolomics and transcriptomics will substantially improve
our capacity to meaningfully stratify patients based on
their microbiome.
We observed a non-significant trend towards an asso-
ciation between antibiotic usage and microbiota com-
position in our study. It is possible that this study was
not sufficiently powered to find an association between
antibiotic use and microbial composition and that the
compositional differences between CRS and healthy
subjects may, at least in part, be antibiotic-mediated. We
are continuing to recruit patients and will examine this
possibility in larger cohorts of cases and controls. Fi-
nally, though the precise cellular source of the cytokines
induced by the pathogenic bacterial community states
cannot be gleaned from our gene expression studies of
human sinus mucosa, we identified significantly up-
regulated genes associated with each state that warrant
further investigation. Despite these limitations, the mi-
crobial and immunological features described herein
provide an explanation for CRS patient heterogeneity
and provide a foundation for improved understanding
of how distinct pathogenic sinus microbiota may col-
lectively and distinctly drive mucosal disease processes
in CRS patients.
Conclusions
Heterogeneity among CRS patients is poorly understood
and represents a significant barrier to disease treatment
and to the development of more effective therapies. This
study validates and extends previous findings that show
collapse of mucosal-associated microbiota in CRS
patients [5, 12, 47]. Here, we demonstrate that CRS
microbiota can exist in at least four compositional states
that are predicted to have distinct functional attributes,
correlate with distinct host immune responses, and asso-
ciate with differential risk for nasal polyps, an important
clinical disease phenotype. The presence of Corynebac-
teriaceae-dominant microbial communities in CRS
patients were associated with increased IL-5 gene
expression and increased risk for nasal polyps while the
remaining three microbial community states were im-
munologically diverse and were not associated with
polyp risk. These findings support prior studies that
characterize the immunological heterogeneity of CRS
patients using similar clustering approaches [20], but by
examining microbial signatures, our studies may provide
an explanation for these diverse immune profiles that
exist within this patient population. The microbial and
immunological features described here may inform
strategies for tailored therapy in this patient population.
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Additional file 6: Supplemental Information. Figure S1A. Lund-MacKay
scores associated with disease state. No differences were observed
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between CRS, CRS+A or CRS+CF patients; B. CRS-CF patients are
significantly younger than CRS+A patients (ANOVA, Tukey’s p = 0.041);
however, no differences in age were observed for pairwise compari-
sons between the other groups (p > 0.05, Tukey’s post hoc test). Fig-
ure S2A. PCoA of an unweighted UniFrac distance matrix colored by
DSI-IIIb and healthy (PERMANOVA p = 0.001, 18.2% variation explained);
B. PCoA of weighted UniFrac distance matrix after dominant sequence reads
associated with the dominant family in each sample were removed
demonstrating that DS still significantly explains variation in community
composition despite removal of the dominant taxon from each sample
(PERMANOVA p = 0.001, 17.6% variation explained).
Figure S3A. Laplace model fit demonstrates three distinct Dirichlet
multinomial mixtures groups. B. Hierarchical cluster analysis using a
weighted-UniFrac distance matrix showing that microbiomes enriched in
Corynebacteriaceae forms a distinct cluster (au p = 100). Heatmap shows
relative abundance of the bacterial general that comprise >90% of the total
sequence reads. C. Reciprocal relationship between Corynebacteriaceae and
Staphylococcaceae. Figure S4. PICRUSt-predicted functional variation across
microbial Dirichlet states shows significant functional differences A. PCoA
of Canberra distance matrix; PERMANOVA p = 0.001, 21.7% of variation
explained) B. PCoA of Bray-Curtis distance matrix; PERMANOVA p = 0.001,
22.0% of variation explained). Figure S5. Expression levels of all host
immune genes measured by QPCR (*indicates Kruskal-Wallis p < 0.05,
q < 0.15; **indicates Kruskal-Wallis p < 0.05, q < 0.05; DS vs. nonCRS).
Table S1–S5. (ZIP 1671 kb)
Additional file 7: Nearest Taxon Sequence Index (NTSI) scores for
PICRUSt predictions. (XLSX 41 kb)
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